<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064114</url>
  </required_header>
  <id_info>
    <org_study_id>PV4300</org_study_id>
    <nct_id>NCT02064114</nct_id>
  </id_info>
  <brief_title>SORT - AF Supervised Obesity Reduction Trial for AF Ablation Patients</brief_title>
  <acronym>SORT-AF</acronym>
  <official_title>Supervised Obesity Reduction Trial for AF Ablation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis:

      Weight reduction in obese patients with atrial fibrillation. Obese patients benefit from an
      obesity treatment after atrial fibrillation ablation.

      Study design:

      A prospective randomized, open-label clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study protocol:

      The purpose of this study is to proof a professional care of overweight patients with
      symptomatic atrial fibrillation, as well as the treatment of the risk factors for atrial
      fibrillation, especially obstructive sleep apnea and hypertension.

      There is a 1:1 randomization. In the intervention group, patients are followed up in a
      6-month intensive care after atrial fibrillation ablation. During the follow up time patients
      will visit the nutritional advice every two weeks for 6 months.

      The Follow-up in the control group is standard of care. At baseline, a screening test for
      obstructive sleep apnea and arterial hypertension will be performed as standard care.

      The documentation of atrial fibrillation after ablation is made possible by the implantation
      of an event recorder before atrial fibrillation ablation.

      Follow up:

      A follow-up will be performed after 3,6 and 12 months in both groups. Patients in the
      intervention group will be followed-up every 2 weeks in the first 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of sustained atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence of sustained atrial fibrillation (&gt;30 seconds) after atrial fibrillation ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coincidence of sleep apnea</measure>
    <time_frame>12 months</time_frame>
    <description>Apnea-hypopnea-index (AHI) &gt; 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Obesity</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional treatment, followed for a period of 3,6 and 12 months after the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intervention group</intervention_name>
    <description>Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>Followed for a period of 3,6 and 12 months after the procedure.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Overweight with a BMI ≥ 30

          -  Obtained written informed consent

          -  Symptomatic atrial fibrillation with indication for ablation

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Permanent atrial fibrillation (failed Cardioversion or episode duration &gt; 12 months)

          -  Previous surgical or interventional therapy of atrial fibrillation

          -  BMI &gt; 40

          -  Pregnant women or women of childbearing potential without a negative pregnancy test
             within 48 hours prior to treatment

          -  History of hemorrhagic diathesis or other coagulopathies

          -  Contraindications for oral anticoagulation

          -  Hyper- or hypothyroidism

          -  Drug or chronic alcohol abuse

          -  Has any condition that would make participation not be in the best interest of the
             subject

          -  Incompliance

          -  Unable to perform athletic exercise due to disease or disability

          -  Resident outside Hamburg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Willems</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Willems</last_name>
    <phone>+ 49 40 7410</phone>
    <phone_ext>59471</phone_ext>
    <email>willems@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herzzentrum der Universität zu Köln</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakob Lueker</last_name>
      <phone>+49 221 478 82851</phone>
      <email>jakob.lueker@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Steven</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakob Lueker</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nele Gessler</last_name>
      <phone>+ 49 40 7410</phone>
      <phone_ext>59471</phone_ext>
      <email>n.gessler@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Katrin Fuerst</last_name>
      <phone>+ 49 40 7410</phone>
      <phone_ext>59471</phone_ext>
      <email>k.fuerst@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Willems</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nele Geßler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMI &gt;40</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

